Stockreport

Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio [Seeking Alpha]

Xeris Biopharma Holdings, Inc.  (XERS) 
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am Check Earnings Report
PDF XERS delivered strong Q4 results: GAAP EPS of $0.06, 43% revenue growth to $85.1M, and initial FY26 guidance above consensus at $375–$390M. XP-8121, XERS's once-weekl [Read more]